房健民

房健民，1993年至1997年在加拿大Dalhousie大學生物系攻讀生物學博士學位，1997-2000年在美國哈佛大學醫學院從事博士后研究。從2000年至2009年，在美國歷任Cell Genesys研究公司研究員，高級研究員，新葯開發項目負責人；Panorama研究所高級研究員，抗體工程研究部主任。2008年榮昌製藥與房健民合資成立了榮昌生物公司。2009年始任同濟大學生命科學與技術學院教授，博士生導師。

主要研究抗腫瘤和自身免疫疾病的生物藥物開發，腫瘤血管新生的分子調控，幹細胞的分化等。發表文章的刊物包括Nature Biotechnology, PNAS, Cancer Research, Molecular Therapy, Developmental Biology等。有多項已授權或公開的發明專利。曾獲中國國家科技進步獎二等獎，加拿大Killam 學者獎，加拿大NSERC博士后獎等。

1. 單克隆抗體和蛋白質工程新葯研究: 單克隆抗體的製備和篩選, 抗體和蛋白質藥物的結構優化, 抗體的人源化, 藥物的臨床前評估, 高表達細胞株的構建; 真核細胞在生物反應器的大規模培養和優化等。

2. 血管新生調控的機理: 腫瘤及視網膜疾病發生過程中血管新生啟動的分子機理；MMP對血管新生的調控; 血管內皮生長因子(VEGF)受體的信號傳導；VEGF佶抗劑藥物研究; Notch 信號途徑對血管內皮細胞的調控等.

3. 免疫學：新型免疫抑製劑對系統性紅斑狼瘡和類風濕關節炎的作用；治療性腫瘤疫苗的研究；T細胞負調控因子對腫瘤免疫的作用等。

4. 幹細胞生物學：骨骼幹細胞的分化及分子調控；機械刺激及細胞間質因子對骨骼幹細胞的分化的影響；誘導多能幹細胞（iPS細胞)的細胞分化；iPS細胞的基因表達。

5. 基因治療：治療性單克隆抗體的基因治療給葯；腫瘤的基因治療。

Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, Vanroey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 57:1263-70. 2008.

Fang J, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. An antibody delivery system for regulated expression of monoclonal antibody at therapeutic level in vivo. Molecular Therapy 15:1153-1159. 2007.

Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, moses MA. repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Research. 67:8736-8741. 2007.

Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nature Biotechnology 23:584-590. 2005.

Fang J. and Jooss K. Rapid generation of high-level antibodies in vitro and in vivo. Discovery Medicine 5:367-370. 2005.

Marler JJ, Fishman SJ, Kilroy SM, Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA. Increased Expression of Urinary Matrix Metalloproteinases Parallels The Extent and Activity of Vascular Anomalies. Pediatrics 116:38-45. 2005.

Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Research 61:5731-5735. 2001.

Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proceedings of the National Academy of Sciences, USA (PNAS) 97:3884-3889. 2000.

Fang J. and Hall B.K. N-CAM is not required for initiation of secondary chondrogenesis: The role of N-CAM in skeletal condensation and differentiation. International Journal of Developmental Biology 43: 335-342. 1999.

Fang J. and Hall B.K. Chondrogenic cell differentiation from membrane bone periostea. Anatomy and embryology 196: 349-362. 1997.

Fang J. and Hall B.K. In vitro differentiation potential of the pe

riosteal cells from a membrane bone, the quadratojugal of the embryonic chick. Developmental Biology 180: 701-712. 1996.

Fang J. and Hall B.K. Differential expression of neural cell adhesion molecule (NCAM) during osteogenesis and secondary chondrogenesis in the embryonic chick. International Journal of Developmental Biology 39: 519-528. 1995.